Drug Repositioning Using Computer-aided Drug Design (CADD)
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Drug repositioning is a method of using authorized drugs for other unusually complex diseases. Compared to new drug development, this method is fast, low in cost, and effective. Through the use of outstanding bioinformatics tools, such as computer-aided drug design (CADD), computer strategies play a vital role in the re-transformation of drugs. The use of CADD's special strategy for target-based drug reuse is the most promising method, and its realization rate is high. In this review article, we have particularly focused on understanding the various technologies of CADD and the use of computer-aided drug design for target-based drug reuse, taking COVID-19 and cancer as examples. Finally, it is concluded that CADD technology is accelerating the development of repurposed drugs due to its many advantages, and there are many facts to prove that the new ligand-targeting strategy is a beneficial method and that it will gain momentum with the development of technology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current pharmaceutical biotechnology - 25(2024), 3 vom: 09., Seite 301-312 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rawat, Sona [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CADD techniques |
|---|
| Anmerkungen: |
Date Completed 27.03.2024 Date Revised 27.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389201024666230821103601 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361039735 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361039735 | ||
| 003 | DE-627 | ||
| 005 | 20240327235255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389201024666230821103601 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1350.xml |
| 035 | |a (DE-627)NLM361039735 | ||
| 035 | |a (NLM)37605405 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rawat, Sona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug Repositioning Using Computer-aided Drug Design (CADD) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Drug repositioning is a method of using authorized drugs for other unusually complex diseases. Compared to new drug development, this method is fast, low in cost, and effective. Through the use of outstanding bioinformatics tools, such as computer-aided drug design (CADD), computer strategies play a vital role in the re-transformation of drugs. The use of CADD's special strategy for target-based drug reuse is the most promising method, and its realization rate is high. In this review article, we have particularly focused on understanding the various technologies of CADD and the use of computer-aided drug design for target-based drug reuse, taking COVID-19 and cancer as examples. Finally, it is concluded that CADD technology is accelerating the development of repurposed drugs due to its many advantages, and there are many facts to prove that the new ligand-targeting strategy is a beneficial method and that it will gain momentum with the development of technology | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CADD techniques | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Drug repositioning | |
| 650 | 4 | |a cancer. | |
| 650 | 4 | |a computer-aided drug designing | |
| 650 | 4 | |a target-based drug repurposing | |
| 700 | 1 | |a Subramaniam, Kanmani |e verfasserin |4 aut | |
| 700 | 1 | |a Subramanian, Selva Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Subbarayan, Saravanan |e verfasserin |4 aut | |
| 700 | 1 | |a Dhanabalan, Subramanian |e verfasserin |4 aut | |
| 700 | 1 | |a Chidambaram, Sashik Kumar Madurai |e verfasserin |4 aut | |
| 700 | 1 | |a Stalin, Balasubramaniam |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Arpita |e verfasserin |4 aut | |
| 700 | 1 | |a Nagaprasad, Nagaraj |e verfasserin |4 aut | |
| 700 | 1 | |a Aruna, Mahalingam |e verfasserin |4 aut | |
| 700 | 1 | |a Tesfaye, Jule Leta |e verfasserin |4 aut | |
| 700 | 1 | |a Badassa, Bayissa |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnaraj, Ramaswamy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d 2000 |g 25(2024), 3 vom: 09., Seite 301-312 |w (DE-627)NLM11369072X |x 1873-4316 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:3 |g day:09 |g pages:301-312 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389201024666230821103601 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 3 |b 09 |h 301-312 | ||